Current regulatory approaches for accessing potential COVID-19 therapies

References

• Kalil AC. Treating COVID-19 - Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials during Pandemics. JAMA - J Am Med Assoc. 2020.
   Google Scholar
• Food and Drug Administration FDA. Emergency Use Authorization (EUA) information, and list of all current EUAs. Available from: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#2019-ncov.
   Google Scholar
• European Medicines Agency. Treatments and vaccines for COVID-19 | European Medicines Agency. [Cited 2020 Apr 21]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19.
   Google Scholar
• Italian Medicines Agency (AIFA). Emergenza COVID-19 | Agenzia Italiana del Farmaco. [Cited 2020 Apr 21]. Available from: https://www.aifa.gov.it/emergenza-covid-19.
   Google Scholar
• Federal Institute for Drugs and Medical Devices. BfArM - Coronavirus SARS-CoV-2. [Cited 2020 Apr 21]. Available from: https://www.bfarm.de/DE/Service/Presse/Themendossiers/Coronavirus/_node.html.
   Google Scholar
• The French National Agency for Medicines and Health Products Safety (ansm). Médicaments - Nos informations de sécurité, avis et recommandations face au COVID - 19 - ANSM : Agence nationale de sécurité du médicament et des produits de santé. [Cited 2020 Apr 24]. Available from: https://www.ansm.sante.fr/Dossiers/COVID-19/Medicaments-Nos-informations-de-securite-avis-et-recommandations-face-au-COVID-19/(offset)/1#paragraph_64595.
   Google Scholar
• Federal agency for medicines and health products (famph). Coronavirus: what medicinal products are used in the fight against COVID-19? | FAMHP. [Cited 2020 Apr 24]. Available from: https://www.famhp.be/en/news/coronavirus_what_medicinal_products_are_used_in_the_fight_against_covid_19.
   Google Scholar
• FrançaK,LitewkaS.Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies.Int J Dermatol.2019;58(7):788.
   Web of Science ®Google Scholar
• LenkC,DuttgeG.Ethical and legal framework and regulation for off-label use: European perspective.Ther Clin Risk Manag.2014;10:537.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments | FDA. [Cited 2020 Apr 24]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-facilitate-development-treatments.
   Google Scholar
• BorysowskiJ,GórskiA.Compassionate use of unauthorized drugs: legal regulations and ethical challenges.Eur J Intern Med.2019;65:12.
   Web of Science ®Google Scholar
• BalasubramanianG,MorampudiS,ChhabraP,GowdaA,ZomorodiB.An overview of compassionate use programs in the european union member states.Intractable Rare Dis Res.2016;5(4):244.
   Google Scholar
• BuhlesWC.Compassionate use: a story of ethics and science in the development of a new drug.Perspect Biol Med.2011;54(3):304.
   Web of Science ®Google Scholar
• Food and Drug Administration (FDA). FDA COMBATING COVID-19 WITH THERAPEUTICS | FDA [Internet]. [cited 2020 Apr 21]. Available from: https://www.fda.gov/media/136832/download.
   Google Scholar
• The French National Agency for Medicines and Health Products Safety (ansm). Plaquenil et Kaletra : les traitements testés pour soigner les patients COVID-19 ne doivent être utilisés qu’à l’hôpital - Point d’information - ANSM : Agence nationale de sécurité du médicament et des produits de santé. [Cited 2020 Apr 24]. Available from: https://www.ansm.sante.fr/S-informer/Points-d-information-Points-d-information/Plaquenil-et-Kaletra-les-traitements-testes-pour-soigner-les-patients-COVID-19-ne-doivent-etre-utilises-qu-a-l-hopital-Point-d-information.
   Google Scholar
• GreinJ,OhmagariN,ShinD,DiazG,AspergesE,CastagnaA,et al.Compassionate use of Remdesivir for patients with severe Covid-19.N Engl J Med.2020;1:1–10Available from: http://www.ncbi.nlm.nih.gov/pubmed/32275812.
   Google Scholar
• ZettlerPJ.Compassionate use of experimental therapies: who should decide?EMBO Mol Med.2015;7(10):1248.
   Web of Science ®Google Scholar
• JeromeRN,EdwardsTL,BoswellHC,BernardGR,HarrisPA,PulleyJM.Recommendations to facilitate expanded access to investigational therapies for seriously ill patients.Acad Med.2016;91(3):305.
   Web of Science ®Google Scholar
• MackeyTK,SchoenfeldVJ.Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.BMC Med.2016;14:17.
   PubMed Web of Science ®Google Scholar
• Association AM.Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, vol. 2019;2020.
   Google Scholar
• U.S. National Library of Medicine. COVID-19 Studies from the World Health Organization Database - ClinicalTrials.gov. [Cited 2020 Apr 21]. Available from: https://clinicaltrials.gov/ct2/who_table.
   Google Scholar